Influenza Vaccines for the World

19-21 April 2017, CHUVUniversity of Lausanne, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Thursday 20th April 2017

SESSION 5:
SPECIAL SESSION

‘Innate and acquired immunity to plant-made influenza VLP vaccines in adults and elderly’
Moderator: Nathalie Charland (Medicago Inc., Quebec, Quebec, Canada)

09.00-09.30
‘Mechanism of plant-made VLP Vaccines I: Focus on the innate response’
Brian J. Ward (McGill University, Montreal, Quebec, Canada)

09.30-10.00
‘Mechanism of plant-made VLP vaccines II: Dendritic cells and adaptive responses’
Connie Michele Krawczyk (McGill University, Montreal, Quebec, Canada)

10.00-10.30
‘Clinical update of plant-made quadrivalent VLP vaccine’
Nathalie Landry (Medicago Inc., Quebec, Quebec, Canada)

Sponsored by MEDICAGO

Medicago

10.30-11.00
Coffee Break & Posters

SESSION 6:
DELIVERY ROUTES

Moderator: Manmohan Singh (Takeda Vaccines, Inc., Cambridge, Massachusetts, USA)

11.00-11.20
‘Clinical development of an inactivated nasal influenza vaccine’
Anna-Karin Maltais (Eurocine Vaccines AB, Solna, Sweden)

11.20-11.40
‘Live attenuated versus inactivated influenza vaccines: Controlling for administration route and other factors’
Yuri M. Vasiliev (St. Petersburg Research Institute of Vaccines and Sera, St Petersburg, Russian Federation)

11.40-12.00
‘Jet delivery of DNA: targeting of hemagglutinin to MHC class II molecules protects rhesus macaques against H1N1 influenza’
Petra Mooij1, Gunnveig Grødeland2, Gerrit Koopman1, Daniella Mortier1, Ivonne G. Nieuwenhuis1, Ernst Verschoor1, Zahra Fagrouch1, Willy M. Bogers1 and Bjarne Bogen2,3 (1 Biomedical Primate Research Centre, Rijswijk, The Netherlands; 2 K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway; 3 Centre for Immune Regulation (CIR), Institute of Immunology, University of Oslo and Oslo University Hospital, Norway)

12.00-12.20
‘The cross-protective potential and the protection-relevant immune mechanisms of whole inactivated virus vaccines are determined by adjuvants and route of immunization’
Yoshita Bhide1, Wei Dong1, Inta Gribonika3, Daniëlle Voshart1, Tjarko Meijerhof1, Jacqueline de Vries-Idema1, Dennis Christensen2, Nils Lycke3, Stephen Norley4, Diane Major5, Sarah Skeldon5, Othmar Engelhardt5 and Anke Huckriede1 (1 University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; 2 Statens Serum Institut, Copenhagen, Denmark; 3 Gothenburg University, Gothenburg, Sweden; 4 Robert Koch Institute, Berlin, Germany; 5 National Institute for Biological Standards and Control (NIBSC), MHRA, Potters Bar, UK)

12.20-12.40
‘Challenges in influenza virus-like particles production: New analytical tools and downstream process optimization’
S.B. Carvalho1,2, J.M. Freire3, R. Silva1, M.G. Moleirinho1, B. Cunha1,2, A.S. Moreira1, F. Monteiro1,2, D. Gaspar3, M.A.R.B.Castanho3, G.J.L. Bernardes3,4, D. Wheatley5, J. Welsh5, R. Gantier6, A. Xenopoulos7, P. M. Alves1,2, C. Peixoto1,2 and M.J.T. Carrondo1,2,8 (1 iBET, Oeiras, Portugal; 2 ITQB-NOVA, Oeiras, Portugal; 3 Instituto de Medicina Molecular, Lisboa, Portugal; 4 University of Cambridge, Cambridge, UK; 5 Pall Life Sciences, UK; 6 Pall Life Sciences, USA; 7 EMD Millipore, USA; 8 FCT/UNL, Caparica, Portugal)

12.40-13.40
Lunch Break & Posters

SESSION 7:
UNIVERSAL INFLUENZA VACCINES – I

Moderator: Sean Tucker (VAXART Inc., South San Francisco, California, USA)

13.40-14.10
‘Progress in clinical development of novel influenza vaccines’
Sarah Gilbert (University of Oxford, Oxford, UK)

14.10-14.40
‘Adjuvanted mini-HA UFV4900 provides protection in a ferret pre-exposure H5N1 challenge model’
Joan E.M. van der Lubbe1, Geert van Amerongen2, Leon de Waal2, Liesbeth Dekking1, Wim Meijberg1, Boerries Brandenburg1, Ted Kwaks1, Hanneke Schuitemaker1, Roland Zahn1, Koert Stittelaar2, Ramon Roozendaal1 and Harmjan Kuipers1 (1 Janssen Vaccines and Prevention BV, Pharmaceutical Companies of Johnson & Johnson, Leiden, The Netherlands; 2 Viroclinics Biosciences BV, Rotterdam, The Netherlands)

14.40-15.10
‘Safety and immunogenicity of a BiondVax-developed universal influenza vaccine (Multimeric-001) followed by an administration of a H5N1 influenza vaccine’
Joshua E. Phillipson1, Tamar Ben-Yedidia1, Eva van Doorn2, Atiqul Islam2, Shimon Hassin2, Ildiko Visontai3, Stephan Norley4, Anke Huckriede5, Henderik W. Frijlink6 and Eelko Hak2 (1 BiondVax Pharmaceuticals Ltd., Ness Ziona, Israel; 2 University of Groningen, Groningen, The Netherlands; 3 National Center for Epidemiology, Budapest, Hungary; 4 Robert Koch Institute, Berlin, Germany; 5 University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 6 Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands)

15.10-15.30
Tea Break & Posters

SESSION 8:
IVW 2017 WORKSHOP

‘Alternative potency assay development for influenza vaccines’

Moderators:
Jonathan L. Bundy and Carrie L. Pierce (National Center for Environmental Health, Centers for Disease Control and Prevention (NCEH/CDC), Atlanta, Georgia, USA)
Othmar G. Engelhardt (National Institute for Biological Standards and Control (NIBSC), South Mimms, Potters Bar, Hertfordshire, UK)

15.30-15.40
Opening Remarks
Othmar Engelhardt (National Institute for Biological Standards and Control (NIBSC) South Mimms, Potters Bar, Hertfordshire, UK)

15.40-15.55
‘Historical and current background on potency assays for influenza vaccines’
Jerry Weir (Center for Biologics Evaluation and Research, Food and Drug Administration (CBER/FDA) Bethesda, Maryland USA)

15.55-16.10
‘The basis for measurement in influenza potency assays and the analytical challenges involved in implementing alternative assays’
Ethan Settembre (Seqirus, Cambridge, MA USA)

16.10-16.25
‘Relevance of current and future potency assays to clinical/in vivo studies’
Kathy Rowlen (InDevR, Boulder, Colorado USA)

16.25-16.40
‘Use of mass spectrometry in the influenza vaccine development pipeline’
Carrie Pierce (National Center for Environmental Health, Centers for Disease Control and Prevention (NCEH/CDC), Atlanta, Georgia, USA)

16.40-16.55
‘Forced degradation studies to support potency assay development’
Othmar Engelhardt (National Institute for Biological Standards and Control (NIBSC), South Mimms, Potters Bar, Hertfordshire, UK)

16.55-17.10
‘Status of current approaches for novel alternative potency assays’
Jonathan Bundy (National Center for Environmental Health, Centers for Disease Control and Prevention (NCEH/CDC), Atlanta, Georgia, USA)

17.10-17.25
‘IFPMA/BARDA Phase I & II potency assay evaluation studies’
Shawn Gilchrist (IFPMA representative)

17.25-17.40
‘Assays for influenza vaccine immunogenicity evaluation and correlates of protection’
Emanuele Montomoli (VisMederi Srl, Siena, Italy/University of Siena, Siena, Italy)

17.40-18.00
General Discussion
All, led by Moderators

 

IVW 2017 Delegates

Login details will be supplied after you have registered for the event.


IVW 2017 Sponsors

  • FluConsult
  • Protein Sciences
  • MedImmune
  • APACI
  • hVIVO
  • ISIRV
  • Eurocine Vaccines
  • Sanofi Pasteur
  • InDevR
  • Inovio
  • Vaxart
  • Fraunhofer
  • Janssen
  • VisMederi
  • Nanopass
  • Biondvax
  • MedicaGo

IVW 2017 Downloads

IVW 2017 Leaflet

IVW 2017 Mailing List

Name
E-mail Address
What is 3+2-1?